版本:
中国

BRIEF-Inotek completes patient recruitment in phase 2 trial of a fixed-dose combination of Trabodenoson and Latanoprost

April 11 Inotek Pharmaceuticals Corp

* Inotek completes patient recruitment in phase 2 trial of a fixed-dose combination (fdc) of Trabodenoson and Latanoprost

* Inotek Pharmaceuticals Corp - Top-line data from FDC study are expected in July Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐